FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE (FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE).
Fluorescein sodium is a fluorescent dye that binds to proteins and accumulates in areas of damaged corneal epithelium, emitting green fluorescence under cobalt blue light, aiding visualization. Benoxinate hydrochloride is a local anesthetic that reversibly blocks sodium channels in nerve cell membranes, inhibiting nerve impulse propagation in corneal and conjunctival tissues.
| Metabolism | Fluorescein sodium: Metabolized to fluorescein monoglucuronide primarily by hepatic glucuronidation; renal excretion. Benoxinate hydrochloride: Hydrolyzed by plasma esterases (pseudocholinesterase) to metabolites, primarily 3-amino-4-propoxybenzoic acid and diethylaminoethanol; further metabolism by liver. |
| Excretion | Fluorescein sodium: Renal (80-90% unchanged within 24-48 hours). Benoxinate: Hepatic metabolism, renal excretion of metabolites (<5% unchanged). |
| Half-life | Fluorescein: Terminal half-life ~4.5 hours (range 3.5-6 hours) after IV; prolonged in renal impairment. Benoxinate: ~1-2 minutes in plasma due to rapid ester hydrolysis. |
| Protein binding | Fluorescein: 70-85% bound to plasma proteins (mainly albumin). Benoxinate: negligible binding due to rapid hydrolysis. |
| Volume of Distribution | Fluorescein: Vd 0.3-0.5 L/kg (distributes into extracellular fluid, does not cross cell membranes readily). Benoxinate: Not applicable due to local action and rapid metabolism. |
| Bioavailability | Topical: Fluorescein not systemically bioavailable; benoxinate systemic bioavailability <1% due to rapid ester hydrolysis in cornea and plasma. |
| Onset of Action | Topical ophthalmic: Benoxinate within 30 seconds; fluorescein staining visible within minutes. |
| Duration of Action | Topical ophthalmic: Benoxinate anesthesia lasts 15-20 minutes; fluorescein staining persists for 20-30 minutes but may be visible longer under blue light. |
One drop of combined solution (containing fluorescein sodium 0.25% and benoxinate hydrochloride 0.4%) instilled into the conjunctival sac prior to diagnostic procedures; may repeat as needed for adequate anesthesia and staining.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required for this topical ophthalmic preparation; systemic absorption is negligible. |
| Liver impairment | No dose adjustment required for this topical ophthalmic preparation; systemic absorption is negligible. |
| Pediatric use | Same as adult dose: one drop of combined solution instilled into the conjunctival sac; use with caution in neonates due to potential systemic toxicity with excessive use. |
| Geriatric use | No specific dose adjustment required; use with caution in patients with decreased tear production or ocular surface disease. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE (FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE).
| Breastfeeding | Fluorescein sodium is excreted into breast milk following intravenous administration, with M/P ratio not established. Topical ophthalmic use leading to minimal systemic absorption is unlikely to pose significant risk to a nursing infant. Benoxinate hydrochloride is a local anesthetic; no data on excretion in breast milk. Use caution in breastfeeding women, especially after systemic administration. The American Academy of Pediatrics considers fluorescein sodium compatible with breastfeeding. |
| Teratogenic Risk | Fluorescein sodium and benoxinate hydrochloride are administered topically and systemically absorbed fluorescein sodium has not been associated with increased risk of congenital anomalies in human studies. However, benoxinate hydrochloride, as a local anesthetic, has limited data; animal studies are inadequate. The risk of teratogenicity is considered low for topical ophthalmic use, but systemic effects cannot be ruled out. FDA Pregnancy Category C (as of labeling; no specific category for combination). First trimester: theoretical risk due to systemic absorption; second and third trimesters: low risk with topical use. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Known hypersensitivity to fluorescein sodium, benoxinate hydrochloride, or any component of the formulation.","Pregnancy or breastfeeding (limited data; use only if clearly needed).","Severe hepatic or renal impairment (risk of fluorescein accumulation).","Patients with pseudocholinesterase deficiency (prolonged anesthetic effect)."]
| Precautions | ["For topical ophthalmic use only; not for injection.","Prolonged use may cause corneal epithelial damage, keratitis, or delayed corneal healing.","Risk of hypersensitivity reactions including anaphylaxis; discontinue if signs of allergy appear.","Corneal edema, epithelial sloughing, and punctate keratitis have been reported with extended anesthetic use.","Contact lens wearers should remove lenses before application; reinsert at least 15 minutes after use.","May interfere with fluorescein angiography interpretation if administered intravenously (not indicated for this purpose).","Use with caution in patients with cardiac disease, hyperthyroidism, or known esterase deficiency (pseudocholinesterase deficiency)."] |
| Food/Dietary |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure and heart rate during systemic administration (e.g., IV fluorescein). Fetal monitoring is not typically required for topical use. If high doses or systemic administration occurs, observe for maternal allergic reactions (e.g., urticaria, hypotension) as these could affect fetal well-being. No specific fetal monitoring recommended. |
| Fertility Effects | No data on fertility effects in humans for fluorescein sodium or benoxinate hydrochloride. Animal studies are lacking. Topical ophthalmic use is unlikely to impact fertility due to minimal systemic absorption. |
| No known food interactions. |
| Clinical Pearls | Do not touch the dropper tip to any surface to avoid contamination. Use immediately after opening single-dose containers. Apply before diagnostic procedures; benoxinate provides anesthesia within 1 minute lasting 15-20 minutes. Fluorescein stains abraded cornea green under blue light. Avoid in patients with sulfonamide allergy (fluorescein contains sulfonamide moiety). Systemic absorption can cause hypotension, bradycardia; monitor in cardiac patients. |
| Patient Advice | Temporary stinging or burning upon instillation is normal. · Avoid rubbing eyes until anesthesia wears off (about 15-20 minutes) to prevent corneal abrasion. · Do not use this medication if you are allergic to sulfonamides or other anesthetics. · Contact lenses should be removed before use and not inserted for at least 30 minutes afterward. · Do not drive or operate machinery until vision returns to normal. |